On February 15, 2019, Shanghai Longyao Biotechnology Co., Ltd. and Nanjing GenScript Biotechnology Co., Ltd. signed a cooperation agreement. With its advantages in biological drug research and development and CDMO technical services, Sirui Bio has carried out comprehensive cooperation in the pharmaceutical research of CAR-T cell therapy.
At the ceremony, Chairman Ye Shengqin welcomed the delegation of Nanjing GenScript Biotechnology Co., Ltd. and introduced our company's achievements in the research and development and transformation of CAR-T and other immune cell technologies in recent years. Chairman Ye Shengqin pointed out that GenScript has advantages in the custom development of biological drugs, and the strong cooperation with GenScript will further accelerate the pace of CAR-T drug application of Longyao Bio. Expected results.
Ye Shengqin, Chairman of Longyao Biotechnology
Ding Xiaojun, Vice President of GenScript's Asia-Pacific Business Department, introduced the company overview and future cooperation areas. Vice President Ding Xiaojun said that Longyao Bio has integrated domestic and foreign experts in the field of immunity, and has made major breakthroughs in the research and development of CAR-T technology and has obvious advantages. Both parties should cherish this cooperation opportunity and jointly promote the development of cell therapy technology, so that the Cooperation has become a successful example of the industry.
Ding Xiaojun , Vice President
The first phase of cooperation between the two parties includes: a new general-purpose CAR-T technology, which overcomes the limitations of autologous CAR-T, has excellent infection and expansion capabilities, and has the same anti-tumor activity in vivo and in vitro as traditional CAR-T , which contributes to the standardization, engineering and industrialization of CAR-T. It can significantly shorten the waiting time of patients and reduce the cost of treatment. In addition, the two parties will cooperate on a new generation of CAR-T technology based on novel costimulatory signals and third signals, which can effectively overcome the immunosuppressive microenvironment of solid tumors and metastatic tumors, and enhance the effect of CAR-T on hematological and solid tumors. Efficacy.
Wang Xin, Vice President of Longyao Biology, delivered a speech
In the follow-up cooperation, Longyao Bio and GenScript will adhere to the principle of combining strengths and complementing each other's advantages to jointly promote the industrialization of CAR-T cell therapy drugs in China.
Wang Xin (right), Vice President of Longyao Biology, and Wang Dongliang (left), Vice President of GenScript Biological Division, sign the cooperation agreementat the meeting site
Group photo of all the participants
GenScript (stock code HK 01548) is a global leader in customized services for biological reagents. After years of rapid development, its business has expanded to precision immunotherapy, customized development of biological drugs (CDMO), biological Reagent products and instruments, as well as the application of synthetic biology to industrial microorganisms. It has built an open technology-driven biopharmaceutical R&D service platform, a plasmid preparation laboratory that complies with GMP standards, and a complete industrial microorganism R&D and industry from enzyme system screening, genetic engineering and protein engineering transformation, fermentation process optimization, and application research. platform. Founded in 2002, the company is headquartered in Nanjing, China. It has production and operation centers in Nanjing, China and New Jersey, the United States. It has also established an Irish R&D center in Europe, and has wholly-owned subsidiaries in the Netherlands and Japan, serving more than 100 countries around the world. Provide high-quality and convenient services with more than 200,000 customers in the region. GenScript has obtained the internationally renowned AAALAC and OLAW certifications.
Longyao Bio is committed to the research and development, technology transformation, product declaration, clinical application research and application promotion of tumor immune cell technology. The company is led by a strong team of scientists led by Professor Fu Yangxin and Professor Yang Xuanming of Shanghai Jiaotong University, etc., in the tumor immune CAR-T, TCR-T and other immune effector cells, immune activation cells, immune regulatory cells in the treatment of malignant hematological tumors, solid tumor technology and products. 14 product pipelines have been laid out, many original achievements have been accumulated, and a number of patents have been declared for key technologies. In July 2018, China Biotechnology Services Holdings Co., Ltd. (stock code 8037.HK) signed a contract to acquire 67% of the equity of Longyao Bio. The listed company has laid out precise detection and precise treatment, and is committed to building a future biotechnology platform. In terms of resources and resources, the development of Longyao Biology is fully guaranteed.